Insider Transactions in Q4 2020 at Ab Cellera Biologics Inc. (ABCL)
Insider Transaction List (Q4 2020)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 15
2020
|
Tryn Stimart Chief Legal Officer |
BUY
Open market or private purchase
|
Indirect |
250
+50.0%
|
$5,000
$20.0 P/Share
|
Dec 15
2020
|
Tryn Stimart Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
250
+50.0%
|
$5,000
$20.0 P/Share
|
Dec 15
2020
|
Michael R Hayden Director |
BUY
Open market or private purchase
|
Indirect |
73,665
+38.39%
|
$1,473,300
$20.0 P/Share
|
Dec 15
2020
|
Michael R Hayden Director |
BUY
Conversion of derivative security
|
Indirect |
117,647
+9.64%
|
-
|
Dec 15
2020
|
Veronique Lecault Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
17,000
+21.63%
|
$340,000
$20.0 P/Share
|
Dec 15
2020
|
Veronique Lecault Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+0.59%
|
$120,000
$20.0 P/Share
|
Dec 15
2020
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+50.0%
|
$100,000
$20.0 P/Share
|
Dec 15
2020
|
John S. Montalbano Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$400,000
$20.0 P/Share
|
Dec 15
2020
|
Peter Thiel Director |
BUY
Conversion of derivative security
|
Indirect |
10,468,907
+45.77%
|
-
|
Dec 15
2020
|
Peter Thiel Director |
BUY
Open market or private purchase
|
Indirect |
3,000,000
+22.76%
|
$60,000,000
$20.0 P/Share
|
Dec 15
2020
|
Dcvc Bio, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
29,105,761
+25.05%
|
-
|
Dec 15
2020
|
John Hamer Director |
BUY
Conversion of derivative security
|
Indirect |
29,105,761
+25.05%
|
-
|
Nov 06
2020
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
270,000
+21.5%
|
$0
$0.33 P/Share
|